Arcturus Therapeutics (ARCT) vs Faeth Therapeutics (FTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arcturus Therapeutics (ARCT) has outperformed Faeth Therapeutics (FTH) over the past year, gaining 19.0% versus a loss of 9.6%. Over five years, ARCT leads with a -81.3% price change compared with -95.0% for FTH. Arcturus Therapeutics is the larger company by market cap ($214.7 million vs $203.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | FTH |
|---|---|---|
| Share price | $7.45 | $7.88 |
| Market cap | $214.73M | $203.65M |
| 1-day change | -1.97% | -9.32% |
| YTD return | +21.53% | -26.15% |
| 1-year return | +19.01% | -9.64% |
| 5-year return | -81.32% | -94.96% |
| EPS (TTM) | $-3.10 | $-22.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $82.03M | — |
| Revenue growth (YoY) | -46.14% | — |
| Net income (latest FY) | $-65.78M | $-21.09M |
| Operating margin | -92.96% | — |
| Net margin | -80.19% | — |
| 52-week high | $17.96 | $42.14 |
| 52-week low | $5.50 | $7.45 |
| Distance from 52-week high | -58.52% | -81.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +218.12% | +612.56% |
| Average volume | 851.45K | 500.25K |
| Shares outstanding | 28.82M | 25.84M |
| Employees | 106 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARCT has outperformed FTH by 28.7 percentage points over the past year.
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
ARCT vs FTH FAQ
Which is bigger, Arcturus Therapeutics or Faeth Therapeutics?
Arcturus Therapeutics (ARCT) is larger, with a market capitalization of $214.73M compared with $203.65M for Faeth Therapeutics (FTH).
Which stock has performed better over the past year, ARCT or FTH?
ARCT returned +19.01% over the past 12 months, compared with -9.64% for FTH (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and Faeth Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.